Company Filing History:
Years Active: 1998-2000
Title: Stephanie A Mengel-Whersat: Innovator in Infectious Disease Research
Introduction
Stephanie A Mengel-Whersat is a prominent inventor based in Hyattsville, MD (US). She has made significant contributions to the field of infectious disease research, particularly through her innovative work on vaccines. With a total of 3 patents, her research focuses on developing immunogenic polypeptides that can combat various strains of infectious bursal disease virus (IBDV).
Latest Patents
Her latest patents include groundbreaking work on chimeric infectious bursal disease virus cDNA clones. These patents detail the expression of chimeric cDNA for immunogenic polypeptides, which incorporate genetic epitopic determinants from both a base IBDV strain and additional strains. The genetic determinants encode amino acids that define epitopes recognized by established monoclonal antibodies. The immunogens produced from this cDNA can be utilized to create vaccines effective against multiple IBDV strains. Furthermore, her research has identified epitopic determinants of lethal IBDV strains, leading to the development of immunogens that confer immunity. Additionally, she has disclosed a monoclonal antibody specific for these lethal strains, along with a vaccine for passive immunization. Her work also highlights the effectiveness of immunogens exhibiting conformational epitopes in the form of virus-like particles for vaccine preparation.
Career Highlights
Stephanie is affiliated with the University System of Maryland, where she continues her research and innovation in the field of infectious diseases. Her work has garnered attention for its potential impact on vaccine development and public health.
Collaborations
She has collaborated with notable colleagues, including Vikram N Vakharia and David B Snyder, to advance her research initiatives.
Conclusion
Stephanie A Mengel-Whersat is a key figure in the development of innovative solutions for infectious diseases. Her contributions through patents and research are paving the way for effective vaccines against IBDV strains.